alpha-N-acetylglucosaminidase


Also found in: Wikipedia.

α-N-a·ce·tyl·glu·co·sam·in·id·ase

(a-sĕ'til-glū-cōs'a-min'i-dās),
An enzyme that hydrolyzes glycosides of N-acetylglucosamine producing the alcohol and N-acetylglucosamine. A deficiency of this enzyme results in mucopolysaccharidosis III B.
Farlex Partner Medical Dictionary © Farlex 2012
References in periodicals archive ?
BioMarin Pharmaceutical announced that it presented interim data from a Phase 1/2 trial for BMN 250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetylglucosaminidase with a peptide derived from insulin-like growth factor 2, for the treatment of Sanfilippo B syndrome or mucopolysaccharidosis IIIB at WORLDSymposium 2018.
BMN250, an investigational enzyme replacement therapy using a novel fusion of recombinant human alpha-N-acetylglucosaminidase (NAGLU) with a peptide derived from insulin-like growth factor 2, is being developed for the treatment of Sanfilippo B syndrome or mucopolysaccharidosis IIIB (MPS IIIB).
Under the agreement announced today, on behalf of the consortium, Institut Pasteur will lead the development programme and will also sponsor the initial Phase I/II clinical study of a gene therapy to replace an enzyme (alpha-N-acetylglucosaminidase) that is missing in brain cells of SanfilippoB patients.